FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2417968046> ?p ?o ?g. }

• W2417968046 endingPage "98" @default.
• W2417968046 startingPage "189" @default.
• W2417968046 abstract "The last few paragraphs will summarize pertinent characteristics of this material in relation to other current sources of factor VIII. First, at a time when safety is the paramount concern in hemophilia therapy, plasma exchange donation offers a product with a very low intrinsic risk of blood borne infection; in many cases, this risk can be equivalent to a single unit of blood. This is much lower than previous versions of commercial factor VIII and much lower than the intrinsic risk of the starting material for current products. We believe this risk is low enough to justify its use without viral inactivation, although certain additional measures, such as the 6-month quarantine devised by Dr. Noel, could increase the margin of safety even further. Note that the principle of limitation of donor exposure is a proven one, which should be effective against any infectious agents, including those unknown to us at this time. Second, at a time when efforts to improve the safety of commercial factor VIII have led to extraordinary increases in cost, factor VIII from plasma exchange donation promises to be relatively inexpensive. Our data indicate that most blood centers could produce factor VIII in this way at 25-50% of the price of the newest commercial products. Finally, there is the matter of supply. At present, commercial factor VIII is in short supply. It may be that worldwide demand for other plasma derivatives, combined with the reduced yield of factor VIII associated with viral inactivation measures, will dictate chronic shortages for the forseeable future. In this unsettled milieu, plasma exchange donation offers a new source of factor VIII, which need not be tied to the supply of, or demand for any other plasma products. Instead, it depends on local initiatives in blood banks and hemophilia centers, and donor activity that can be tailored specifically to the needs of hemophilia patients. Thus, in spite of the impressive advances in the safety of commercial factor VIII which have recently been implemented, we believe there is a place for single donor cryoprecipitate from plasma exchange donation in the treatment of hemophilia and other bleeding disorders in the 1990's. Its use should be more widely and more extensively investigated." @default.
• W2417968046 created "2016-06-24" @default.
• W2417968046 creator A5033018412 @default.
• W2417968046 creator A5084729228 @default.
• W2417968046 date "1990-01-01" @default.
• W2417968046 modified "2023-09-23" @default.
• W2417968046 title "Plasma exchange donation of cryoprecipitate after DDAVP stimulation: an alternative source of factor VIII." @default.
• W2417968046 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2106687" @default.
• W2417968046 hasPublicationYear "1990" @default.
• W2417968046 type Work @default.
• W2417968046 sameAs 2417968046 @default.
• W2417968046 citedByCount "1" @default.
• W2417968046 crossrefType "journal-article" @default.
• W2417968046 hasAuthorship W2417968046A5033018412 @default.
• W2417968046 hasAuthorship W2417968046A5084729228 @default.
• W2417968046 hasConcept C126322002 @default.
• W2417968046 hasConcept C138885662 @default.
• W2417968046 hasConcept C162324750 @default.
• W2417968046 hasConcept C177713679 @default.
• W2417968046 hasConcept C194051981 @default.
• W2417968046 hasConcept C203014093 @default.
• W2417968046 hasConcept C2775933685 @default.
• W2417968046 hasConcept C2778137410 @default.
• W2417968046 hasConcept C2778258694 @default.
• W2417968046 hasConcept C41895202 @default.
• W2417968046 hasConcept C50440223 @default.
• W2417968046 hasConcept C50522688 @default.
• W2417968046 hasConcept C71924100 @default.
• W2417968046 hasConcept C89560881 @default.
• W2417968046 hasConceptScore W2417968046C126322002 @default.
• W2417968046 hasConceptScore W2417968046C138885662 @default.
• W2417968046 hasConceptScore W2417968046C162324750 @default.
• W2417968046 hasConceptScore W2417968046C177713679 @default.
• W2417968046 hasConceptScore W2417968046C194051981 @default.
• W2417968046 hasConceptScore W2417968046C203014093 @default.
• W2417968046 hasConceptScore W2417968046C2775933685 @default.
• W2417968046 hasConceptScore W2417968046C2778137410 @default.
• W2417968046 hasConceptScore W2417968046C2778258694 @default.
• W2417968046 hasConceptScore W2417968046C41895202 @default.
• W2417968046 hasConceptScore W2417968046C50440223 @default.
• W2417968046 hasConceptScore W2417968046C50522688 @default.
• W2417968046 hasConceptScore W2417968046C71924100 @default.
• W2417968046 hasConceptScore W2417968046C89560881 @default.
• W2417968046 hasLocation W24179680461 @default.
• W2417968046 hasOpenAccess W2417968046 @default.
• W2417968046 hasPrimaryLocation W24179680461 @default.
• W2417968046 hasRelatedWork W161407957 @default.
• W2417968046 hasRelatedWork W1966325262 @default.
• W2417968046 hasRelatedWork W1987540852 @default.
• W2417968046 hasRelatedWork W1997621633 @default.
• W2417968046 hasRelatedWork W2014171491 @default.
• W2417968046 hasRelatedWork W2070845468 @default.
• W2417968046 hasRelatedWork W2355549667 @default.
• W2417968046 hasRelatedWork W2383918509 @default.
• W2417968046 hasRelatedWork W2406164672 @default.
• W2417968046 hasRelatedWork W2905563707 @default.
• W2417968046 hasVolume "324" @default.
• W2417968046 isParatext "false" @default.
• W2417968046 isRetracted "false" @default.
• W2417968046 magId "2417968046" @default.
• W2417968046 workType "article" @default.